Cancer Treatment Today

Both allogeneic and autologous hematopoietic cell transplant (HCT) recipients are at increased risk for a variety of infections based upon their degree of immunosuppression and exposures, more so the allogeneic transplant recipients. The types of infections to which these hosts are most vulnerable can be roughly divided based upon their temporal relation to the transplantation: Preengraftment — less than three weeks mmediate postengraftment —

Lay Summary: Not much is known about NK1 T lymphomas. This post briefly describes what is known. This kind of lymphoma tend to be indolent but not all that much is known about hatural history of these neoplasms and some patients do poorly. Patients with natural killer T (NK/T) -cell lymphomas have poor survival outcome, and for this condition there is no optimal therapy. A recent review found that following treatments tend to be used: Patients received

Lay Summary: Autologous stem cell transplantation is standard for relapsed non-Hodgkin's lymphoma.   Patients with aggressive and intermediate non-Hodgkin's lymphoma (NHL) treated at first diagnosis with polychemotherapy alone or combined chemoradiotherapy can achieve high response rates . However, patients with relapsed or progressive disease still have a poor prognosis. High-dose chemotherapy (HDCT) followed by autologous stem cell transplantation

Lay Summary: Autologous stem cell transplantation is an investigational modality for Ewing and PNET. Initial chemotehrapy is recommended, although there is no one superior regimen. The INT-0091 study from the COG reported no benefit with the addition of IE to a standard backbone of vincristine, actinomycin-D, cyclophosphamide, and doxorubicin (VACD) . In the second Intergroup Ewing Sarcoma Study (IESS-2), the addition of 5-fluorouracil (5-FU) failed

Medulloblastoma is treated primarily with surgical excision followed by radiation therapy and chemotherapy. When there is spinal extension, craniospinal radiation is standard. Inoperable medulloblastomas are often treated iwth chemotherapy but there is no randomized prospective evidence to support this. This is especially so in adults, in whom this disease is much less common and in whom it appears to behave distinctly differently. 30% of cases occur

Neupogen is often used to mobilize hematopoietic progenitor cells into the peripheral blood for collection by leukophereses for members who are undergoing peripheral blood progenitor cell". It is FDA approved: "NEUPOGEN® (filgrastim) is indicated for the mobilization of hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis. Mobilization allows for the collection of increased numbers of progenitor cells capable

Lay Summary: Transplants for transformed follicular lymphoma are supported by follicular lymphoma (transformed) guidelines of the NCCN. There is trial evidence supporting this approach. Takvorian and colleagues (1987) studied 49 patients with either high-grade (n = 29), intermediate-grade (n =14) or low-grade (n = 6) lymphoma. All patients were considered to have a poor prognosis either due to relapse (n = 41) or poor prognostic factors (n = 8).

Lay Summary: Stem cell transplantation is standard of care for mantle cell lymphoma. Mantle cell lymphoma is a fairly recently identified subtype of non-Hodgkin's lymphoma. Regarded as a low-grade tumour in previous classifications, it has a median survival of only 36 months and is incurable by current treatment approaches. Widespread disease is usually present at diagnosis involving lymph nodes, spleen, bone marrow and extranodal sites such as the

Summary: NHL is currently the second most frequent indication for autologous hematopoietic stem cell transplantation. It is not a useful treatment option for all patients with NHL, but in certain circumstances, autologous stem cell transplantation does provide patients the best opportunity for cure. Diffuse large-cell lymphoma is the most common form of NHL, and autologous stem cell transplantation has been shown to be beneficial in some subsets

Some 20-30 % of patients with Hodgkin's lymphoma achieve a remission and then relapse. In general, the longer the initial complete remission, the better the outlook with any form of salvage therapy. A variety of treatment regimens have been used for patients with relapsed Hodgkin's disease. In addition to MOPP or ABVD in patients who received the opposite regimen initially, a number of other treatments have been used. Unfortunately, the number of